hydroxybutanoic acid pentanoate | 30435-94-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: hydroxybutanoic acid pentanoate
• 英文别名: 4-Pentanoyloxybutanoic acid
• CAS: 30435-94-0
• 化学式: C₉H₁₆O₄
• 分子量: 188.224
• InChiKey: MZLMBQYMMSELEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-pentenyl pentanoate 在 cobalt(II) acetate 氧气 作用下， 生成 hydroxybutanoic acid pentanoate
  参考文献：
  名称：

  Zamarlik,H., Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques, 1970, vol. 271, p. 1138 - 1141

  摘要：

  DOI：

文献信息

• [EN] A TAG FOR LABELING BIOMOLECULES<br/>[FR] ÉTIQUETTE POUR MARQUER DES BIOMOLÉCULES
  申请人：SHANGHAI POLARIS BIOLOGY CO LTD

  公开号：WO2020228734A1

  公开（公告）日：2020-11-19

  Provided is a tag for labeling a biomolecule, comprising a polymer backbone, one or more pendant moieties, and an end group capable of binding to the biomolecule, wherein each of the pendant moieties is attached to the polymer backbone and capable of chelating with an element. Also provided is a conjugate, comprising a biomolecule covalently coupled with the tag.

  提供了一种用于标记生物分子的标签，包括聚合物骨架，一个或多个侧基团和一个能够与生物分子结合的末端基团，其中每个侧基团连接到聚合物骨架并能够与元素螯合。同时提供了一个共轭物，其中包括与标签共价耦合的生物分子。
• Taxane coatings for implantable medical devices
  申请人：Reyes Priscilla

  公开号：US20070212394A1

  公开（公告）日：2007-09-13

  This disclosure relates to implantable medical devices coated with a taxane therapeutic agent, such as paclitaxel, in one or more solid form(s) having varying dissolution rates. Particularly preferred coatings comprise amorphous and/or solvated solid forms of taxane therapeutic agents that provide durable coatings that release the taxane over a desired period of time, which can be varied in the absence of a polymer by selecting the type and amount of solid forms of the taxane therapeutic agent in the coating. Other preferred embodiments relate to methods of coating medical devices and methods of treatment. The coatings can provide a sustained release of the taxane therapeutic agent within a body vessel without containing a polymer to achieve the desired rate of paclitaxel elution.

  本公开涉及涂有紫杉醇治疗剂（如紫杉醇）的植入式医疗器械，其具有不同溶解速率的一个或多个固态形式的涂层。特别优选的涂层包括无定形和/或溶剂化的紫杉醇治疗剂的固态形式，其提供持久的涂层，可以在不含聚合物的情况下通过选择涂层中的治疗剂的固态形式的类型和数量来改变所需的释放时间。其他优选实施例涉及涂覆医疗器械的方法和治疗方法。这些涂层可以在不含聚合物的情况下提供紫杉醇治疗剂的持续释放，以达到所需的紫杉醇溶出速率。
• DRUG DELIVERY MEDICAL DEVICE
  申请人：Micell Technologies, Inc.

  公开号：US20140371717A1

  公开（公告）日：2014-12-18

  A medical device that releases a pharmaceutical agent to a target site is disclosed. The medical device includes a balloon, and a coating on at least a portion of the balloon. Each particle of the particles of the pharmaceutical agent is at least partially encapsulated in a polymer layer. The method includes the steps of providing a device including a balloon, and a coating on at least a portion of the balloon, the coating including particles of a pharmaceutical agent, and each particle of the pharmaceutical agent is at least partially encapsulated in a polymer layer; positioning the device to allow the balloon to reach the target site; and inflating the balloon of the device.

  公开了一种释放药物剂量到目标部位的医疗设备。该医疗设备包括一个气球，以及气球至少一部分的涂层。药物剂量的每个颗粒都至少部分地被聚合物层包裹。该方法包括以下步骤：提供一个包括气球和气球至少一部分的涂层的设备，涂层包括药物剂量的颗粒，每个药物剂量的颗粒都至少部分地被聚合物层包裹；将该设备定位到允许气球到达目标部位；以及充气该设备的气球。
• Medical devices incorporating deuterated rapamycin for controlled delivery thereof
  申请人：——

  公开号：US20030130206A1

  公开（公告）日：2003-07-10

  Deuterated rapaymcin can be controllably introduced target locations within the patient's body by using an implantable medical device having a structure incorporated with a therapeutic agent comprising a deuterated rapamycin. Representative deuterated rapamycins include epi-7-deuteromthyl rapamycin, 7,43-d 6 rapamycin, 7-deuteromethyl rapamycin and 31,42-d 2 -rapamycin and isomers thereof, and mixtures thereof. The deuterated rapamycin can also be glycosylated.

  通过使用植入式医疗器械，该器械结构中含有一种疗效剂量包括重氘化雷帕霉素的药物，可以在患者体内的目标位置中可控地引入重氘化雷帕霉素。代表性的重氘化雷帕霉素包括epi-7-deuteromthyl雷帕霉素、7,43-d6雷帕霉素、7-deuteromethyl雷帕霉素和31,42-d2-雷帕霉素及其异构体和混合物。重氘化雷帕霉素也可以被糖基化。
• MEDICAL DEVICES CONTAINING RAPAMYCIN ANALOGS
  申请人：Abbott Laboratories

  公开号：US20160220739A1

  公开（公告）日：2016-08-04

  A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature. Drugs that are suitable for use in this invention include, but are not limited to drugs of Formula (I). The drugs of Formula (I) can be used in combination with another drug including those selected from anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, cytotoxic drugs, agents that inhibit cytokine or chemokine binding, cell de-differentiation inhibitors, anti-lipaedemic agents, matrix metalloproteinase inhibitors, cytostatic drugs, or combinations of these drugs.

  一种医疗器械包括一个支撑结构，该支撑结构能够容纳或支撑一种药学上可接受的载体或赋形剂，该载体或赋形剂可以含有一个或多个治疗剂或物质，其中载体最好在其表面包含一层涂层，该涂层含有治疗物质，例如药物。适用于本发明的医疗器械的支撑结构包括但不限于冠状动脉支架、外周支架、导管、动静脉移植物、旁路移植物和用于血管系统的药物输送球。适用于本发明的药物包括但不限于公式（I）中的药物。公式（I）中的药物可以与另一种药物结合使用，包括从抗增殖剂、抗血小板剂、抗炎剂、抗血栓剂、细胞毒性药物、抑制细胞因子或趋化因子结合的药物、细胞去分化抑制剂、降脂药、基质金属蛋白酶抑制剂、细胞周期停滞药或这些药物的组合中选择的药物。